Berenice Gitomer, PhD
Research Professor, Medicine-Renal Med Diseases/Hypertension

Publications

• Yang X, Wang W, Gitomer B, Cadnapaphornchai MA, Xing F, Chonchol M. Imaging Biomarkers in Young Patients With ADPKD. Kidney Int Rep. 2023 Oct;8(10):2153-2155. PubMed PMID: 37850021
• Kleczko EK, Nguyen DT, Marsh KH, Bauer CD, Li AS, Monaghan MT, Berger MD, Furgeson SB, Gitomer BY, Chonchol MB, Clambey ET, Zimmerman KA, Nemenoff RA, Hopp K. Immune checkpoint activity regulates polycystic kidney disease progression. JCI Insight. 2023 Jun 22;8(12). PubMed PMID: 37345660
• Steele CN, Oh ES, Wang W, Farmer-Bailey H, Gitomer BY, Chonchol M, Nowak KL. Cerebrovascular Pulsatility Index Is Reduced in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2023;54(5-6):165-174. PubMed PMID: 37231790
• Perrone RD, Oberdhan D, Ouyang J, Bichet DG, Budde K, Chapman AB, Gitomer BY, Horie S, Ong ACM, Torres VE, Turner AN, Krasa H. OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD. Kidney Int Rep. 2023 May;8(5):989-1001. PubMed PMID: 37180499
• Nguyen DT, Kleczko EK, Dwivedi N, Monaghan MT, Gitomer BY, Chonchol MB, Clambey ET, Nemenoff RA, Klawitter J, Hopp K. The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. JCI Insight. 2023 Jan 10;8(1). PubMed PMID: 36422996
• Klawitter J, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Christians U, Klawitter J. Kynurenines in polycystic kidney disease. J Nephrol. 2023 Jan;36(1):83-91. PubMed PMID: 35867237
• Monaghan M-LT, Nguyen D, Berger MD, D'Alessandro A, Cendali FI, Gitomer BY, Chonchol M, Hopp K. Obesity and PKD: Mechanistic studies using the Pkd1RC/RC model. J Am Soc Nephrol. 2023 Nov; S:204.
• Steele C, Coleman ER, George D, Farmer-Bailey H, Ramanathan S, Gregory A, Wang W, Gitomer BY, Chonchol M, Thomas E, Kline TL, Nowak KL. Time-restricted feeding ans autosomal dominant polycystic kidney disease: A pilot randomized clinical trial. J Am Soc Nephrol. 2023 Nov; S:206.
• Nowak KL, You Z, Steele C, Gitomer BY, Chonchol M, Klawitter J. Kynurenines and change in body mass index in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2023 Nov; S:206.
• Gitomer BY, Wang W, George D, Nowak KL, Britz M, Klawitter J, Jovanovich A, You Z, Farmer B, Chonchol M. Baseline characteristics of participants in statin therapy in patients with early-stage ADPKD clinical trial.J Am Soc Nephrol. 2023 Nov; S:209.
• Wang W, You Z, Steele C, Gitomer BY, Chonchol M, Nowak KL. Changes in tubular biomarkers with dietary intevention and metformin in patients with autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol. 2023 Nov; S:212.
• Zheng B, Gitomer BY, Nowak KL, You Z, Chonchol M. Pregnancy and its association with total kidney volume in nulliparous women with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2023 Nov; S:214.
• Dwivedi N, Gitomer BY, Edelstein CL, Chonchol M, Hopp K, Brunt VE. Vascular dysfunction in the C57Bl/6J;Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease mimics human disease. J Am Soc Nephrol. 2023 Nov; S:508.
• Nguyen DT, Kleczko EK, Dwivedi N, Monaghan MT, Gitomer BY, Chonchol MB, Clambey ET, Nemenoff RA, Klawitter J, Hopp K. The tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. JCI Insight. 2022 Nov 24. [Epub ahead of print] PubMed PMID: 36422996
• Hoover E, Perrone RD, Rusconi C, Benson B, Dahl NK, Gitomer B, Manelli A, Mrug M, Park M, Seliger SL, Phadnis MA, Thewarapperuma N, Watnick TJ. Design and Basic Characteristics of a National Patient-Powered Registry in ADPKD. Kidney360. 2022 Aug 25;3(8):1350-1358. PubMed PMID: 36176661
• Klawitter J, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Christians U, Klawitter J. Kynurenines in polycystic kidney disease. J Nephrol. 2022 Jul 22. [Epub ahead of print] PubMed PMID: 35867237
• Klawitter J, Sempio C, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Christians U, Klawitter J. Endocannabinoid System in Polycystic Kidney Disease. Am J Nephrol. 2022;53(4):264-272. PubMed PMID: 35263737
• Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, Nguyen DT, Bing K, Poudyal B, Johnson GC, Jackman MR, Miller M, Steele CN, Serkova NJ, MacLean PS, Nemenoff RA, Gitomer B, Chonchol M, Nowak KL. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022 Jan 21;25(1):103697. PubMed PMID: 35059607
• Hopp K, Kleczko EK, Gitomer BY, Chonchol M, Klawitter J, Christians U, Klawitter J. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease. Am J Physiol Renal Physiol. 2022 Mar 1;322(3):F258-F267. PubMed PMID: 35037466
• Steele C, You Z, Gitomer BY, Brosnahan GM, Abebe KZ, Braun WE, Chapman AB, Harris PC, Perrone RD, Steinman TI, Torres VE, Yu ASL, Chonchol M, Nowak KL. PKD1 Compared With PK D2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies. Kidney Int Rep. 2022 Jan;7(1):117-120. PubMed PMID: 35005320
• Nowak KL, Farmer-Bailey H, Wang W, You Z, Steele C, Cadnapaphornchai MA, Klawitter J, Patel N, George D, Jovanovich A, Soranno DE, Gitomer B, Chonchol M. Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2022 Feb;17(2):240-250. PubMed PMID: 34907021
• Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol MB. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2022 Apr;79(4):518-526. PubMed PMID: 34391872
• Gitomer B, You Z, Brosnahan G, Wang W, Hopp K, Nowak KL, Jovanovich A, Chapman A, Perrone R, Torres V, Tu A, Chonchol M. Antibiotic use and kidney stone disease in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2022 33(Suppl.2);S159.
• Gitomer B, Yu Z, Brosnahan G, Wang W, Hopp K, Nowak KL, Chapman A, Perrone R, Torres V, Yu A, Chonchol M. Systemic inflamation and kidney stone disease in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2022 33(Suppl.2);S159.
• Gitomer B, You Z, Brosnahan G, Wang W, Hopp K, Nowak KL, Chapman A, Perrone R, Torres V, Yu A, Chonchol M. Urinary clusterin associates with height corrected total kidney volume in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2022 33(Suppl.2);S159.
• Steele CN, Oh ES, Streumph T, Farmer-Bailey H, Gitomer B, Chonchol M, Nowak KL. Cerebrovascular function in early-state autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol. 2022 33(Suppl.2);S155-156.
• Steele CN, Coleman E, Streumph T, George D, Winslow C, Gitomer B, Chonchol M. Altitude, resting metabolic rate, and autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol. 2022 33(Suppl.2);S156.
• Klawitter J, Smith PH, Chonchol M, Gitomer BY, Klawitter J. Microbiome-related changes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2022 33(Suppl.2);S159-160.
• Hoover E, Benson B, Dahl N, Gitomer B, Holliday V, Kleber K, Park M, Perrone R, Phadnis M, Rusconi C, Seliger S, Thewarapperuma N, Oberdhan B. Pain in ADPKD: Results from a National patient powered registry. Am J Kidney Dis. 2022 Apr;79 (4) Suppl 2: S32.
• Baliga MM, Klawitter J, Christians U, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Klawitter J. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. Sci Rep. 2021 Mar 23;11(1):6629. PubMed PMID: 33758231
• Pereira RC, Gitomer BY, Chonchol M, Harris PC, Noche KJ, Salusky IB, Albrecht LV. Characterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD. JBMR Plus. 2021 Apr;5(4):e10464. PubMed PMID: 33869988
• Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and Obesity and Progression of ADPKD. Clin J Am Soc Nephrol. 2021 Jun;16(6):908-915. PubMed PMID: 34117082
• Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol MB. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2021 Aug 12. [Epub ahead of print] PubMed PMID: 34391872
• Nowak KL, Murray K, You Z, Gitomer B, Brosnahan G, Abebe KZ, Braun W, Chapman A, Harris PC, Miskulin D, Perrone R, Torres V, Steinman T, Yu A, Chonchol M. Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Med. 2021 Jul-Aug;3(4):536-545.e1. PubMed PMID: 34401721
• Gitomer B, Pereira R, Salusky IB, Stoneback JW, Isakova T, Cai X, Dalrymple LS, Ofsthun N, You Z, Malluche HH, Maddux F, George D, Torres V, Chapman A, Steinman TI, Wolf M, Chonchol M. Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2021 Apr;99(4):977-985. PubMed PMID: 32926884
• Nguyen D, Kleczko EK, Dwivedi N, Gitomer BY, Chonchol M, Nemenoff R, Klawitter J, Hopp K. Dysregulated tryptophan metabolism promotes polycystic kidney disease progression. J Am Soc Nephrol. 2021 32:392
• Nowak KL, Catenacci V, Kline TL, Wang W, You Z, Bing K, Poudyal B, Steele C, Chonchol M, Gitomer BY. Weight loss to slow cyst growth in autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol 2021 32:404
• Steele C, You Z, Farmer-Bailey H, Gitomer BY, Chonchol M, Nowak KL. Overweight and obesity predict kidney growth in children and young adults with ADPKD. J Am Soc Nephrol 2021 32:404
• Steele C, Klawitter J, Wang W, You Z, Catenacci V, Streumph T, George D, Gitomer BY, Brosnahan GM, Chonchol M, Nowak KL. Metabolomic changes over 1 year following drug or lifestyle interventions in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2021 32:405
• Hoover R, Benson BA, Dahl NK, Gitomer BY, Manelli A, Mrug M, Park M, Rusconi C, Seliger SL, Perrone RD, Watnick TJ. Two years in: The development of basic characreristics of a national patient-powered registry in ADPKD. J Am Soc Nephrol 32:405
• Nowak KL, Farmer-Bailey H, Wang W, You Z, Steele C, Cadnapaphornchai MA, Klawitter J, Patel N, George D, Jovanovich A, Soranno D, Gitomer BY, Chonchol M. Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol 2021 32:406
• Steele C, You Z, Gitomer BY, Brosnahan GM, Harris PC, Torres VE, Abebe KZ, Steinman TI, Yu AS, Perrone RD, Braun WE, Chapman AB, Chonchol M,Nowak KL. PKD1 compared with PKD2 genotype and cardiac hospitalizations in the HALT-PKD studies. J Am Soc Nephrol. 2020; 31: 488
• Wang W, You Z, Gitomer BY, Brosnahan GM, Harris PC, Miskulin D, Torres VE, Abebe KZ, Steinman TI, Ye AS, Perrone RD, Braun WE, Chapman AB, Chonchol M, Nowak KL. Overweight and obesity are predictors of pain in the HALT-PKD studies. J Am Soc Nephrol. 2020;31:500
• Hoover E, Baron D, Benson BA, Gitomer BY, Kleber KR, Manelli A, Mrug M, Park M, Rusconi C, Seliger SL, Perrone RD, Watnick T. Design and basic characteristics of a National patient registry in ADPKD. J Am Soc Nephrol. 2020;31:501.
• Farmer-Bailey H, Cadnapaphornchai MA, You Z, George D, Wang W, Jovanovich A, Soranno D, Gitomer BY, Chonchol M, Nowak KL. Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2020;31:503
• Gitomer B, Pereira R, Salusky IB, Stoneback JW, Isakova T, Cai X, Dalrymple LS, Ofsthun N, You Z, Malluche HH, Maddux F, George D, Torres V, Chapman A, Steinman TI, Wolf M, Chonchol M. Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2020 Sep 11. [Epub ahead of print] PubMed PMID: 32926884
• Griffin BR, You Z, Noureddine L, Gitomer B, Perrenoud L, Wang W, Chonchol M, Jalal D. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results. Am J Nephrol. 2020;51(6):473-479. PubMed PMID: 32541154
• Nowak KL, Farmer-Bailey H, Cadnapaphornchai MA, You Z, George D, Wang W, Jovanovich A, Soranno DE, Gitomer B, Chonchol M. Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants. Contemp Clin Trials Commun. 2020 Sep;19:100635. PubMed PMID: 33294724
• Brosnahan GM, You Z, Wang W, Gitomer BY, Chonchol M. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials. Curr Hypertens Rev. 2020 Aug 17. [Epub ahead of print] PubMed PMID: 32807060
• Hopp K, Cornec-Le Gall E, Senum SR, Te Paske IBAW, Raj S, Lavu S, Baheti S, Edwards ME, Madsen CD, Heyer CM, Ong ACM, Bae KT, Fatica R, Steinman TI, Chapman AB, Gitomer B, Perrone RD, Rahbari-Oskoui FF, Torres VE, Harris PC. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 2020 Feb;97(2):370-382. PubMed PMID: 31874800
• Pereira RC, Gitomer BY, Harris PC, Salusky IB, Albrecht LV. Primary cilia defects reflect specific bone cell activity in human ADPKD osteoblasts. J Am Soc Nephrol. 2020; 31:495
• Nowak KL, Gitomer B, Farmer-Bailey H, Wang W, Malaczewski M, Klawitter J, You Z, George D, Patel N, Jovanovich A, Chonchol M. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial. Am J Kidney Dis. 2019 Aug;74(2):213-223. PubMed PMID: 30803706
• Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. CD8( ) T cells modulate autosomal dominant polycystic kidney disease progression. Kidney Int. 2018 Dec;94(6):1127-1140. PubMed PMID: 30249452
• Nowak KL, Wang W, Farmer-Bailey H, Gitomer B, Malaczewski M, Klawitter J, Jovanovich A, Chonchol M. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1493-1501. PubMed PMID: 30228110
• Nowak KL, Chonchol M, You Z, Gupta M, Gitomer B. Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study?. Clin Nephrol. 2018 Mar;89(3):196-204. PubMed PMID: 29035198
• Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 Feb;29(2):571-578. PubMed PMID: 29118087
• Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2017 May;2(3):442-450. PubMed PMID: 29142971
• Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2017 Nov 8. [Epub ahead of print] PubMed PMID: 29118087
• Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1461-1469. PubMed PMID: 28705885
• Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M. Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2017 Feb 1;32(2):342-347. PubMed PMID: 28186577
• Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M. Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2016 Mar 21. [Epub ahead of print] PubMed PMID: 27001648
• Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U, Schrier RW, Gitomer B, Cadnapaphornchai MA. Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1534-41. PubMed PMID: 26224879
• Perrone RD, Neville J, Chapman AB, Gitomer BY, Miskulin DC, Torres VE, Czerwiec FS, Dennis E, Kisler B, Kopko S, Krasa HB, LeRoy E, Castedo J, Schrier RW, Broadbent S. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2015 Oct;66(4):583-90. PubMed PMID: 26088508
• Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015 Jul;88(1):17-27. PubMed PMID: 25786098
• Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW. Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1198-206. PubMed PMID: 25234311
• Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014 Nov;25(11):2399-418. PubMed PMID: 24925719
• Guay-Woodford LM, Henske E, Igarashi P, Perrone RD, Reed-Gitomer B, Somlo S, Torres VE, Ketchum CJ, Star RA, Flessner MF, Rasooly RS. Filling the holes in cystic kidney disease research. Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1799-801. PubMed PMID: 24903391
• Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014 May;9(5):889-96. PubMed PMID: 24721893
• Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB, HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11;371(24):2255-66. PubMed PMID: 25399733
• Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD, HALT-PKD Trial Investigators. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11;371(24):2267-76. PubMed PMID: 25399731
• Klawitter J, Zafar I, Klawitter J, Pennington AT, Klepacki J, Gitomer BY, Schrier RW, Christians U, Edelstein CL. Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD Rat model of polycystic kidney disease. BMC Nephrol. 2013 Jul 31;14(1):165. [Epub ahead of print] PubMed PMID: 23902712
• Helal I, McFann K, Reed B, Yan XD, Schrier RW. Changing referral characteristics of patients with autosomal dominant polycystic kidney disease. Am J Med. 2013 Sep;126(9):832.e7-832.e11. PubMed PMID: 23830538
• Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2013 Feb;28(2):380-5. PubMed PMID: 23222419
• Reed-Gitomer B. Autosomal dominant polycystic kidney disease: cardiovascular complications. Curr Hypertens Rev. 2013 Feb;9(1):1. PubMed PMID: 23971637
• Reed-Gitomer B. Vitamin D deficiency: a nontraditional risk factor in polycystic kidney disease?. Am J Physiol Renal Physiol. 2013 Oct 1;305(7):F975-6. PubMed PMID: 23804446